Lunit: Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading...

Lunit 6 posters unveil new tumor microenvironment insights and the predictive power of Lunit SCOPE across diverse cancer types at SITC 2023 SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of...

Lunit and collaborators demonstrate the predictive value and analytical prowess of Lunit's AI-biomarker platform in a wide range of cancer types and clinical practices SEOUL, South Korea, May 10, 2023 /PRNewswire/ -- Lunit...